---
title: "l-mind"
slug: "l-mind"
date: "2024-05-07"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ªï¼š[[double_hit_and_double_expressors_in_lymphoma]]

# l-mind

- At a median follow-up of 13.2 months, the
  - objective response rate (ORR) was 60% (48/80 patients, efficacy set),
  - complete response (CR) rate was 43% (34/80 patients),
  - partial response (PR) rate was 18% (14/80 patients).

Cyclea Tafasitamab dosing schedule10,11 Lenalidomide dosing schedule in L-MIND9
Cycle 1 Days 1, 4, 8, 15, and 22 Days 1-21
Cycles 2 and 3 Days 1, 8, 15, and 22 Days 1-21
Cycles 4 to 12 Days 1 and 15 Days 1-21

- [Clinical Treatment Guidelines for Tafasitamab plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma | The Oncologist | Oxford Academic](https://academic.oup.com/oncolo/article/28/3/199/6989635)
